Atypical neuroleptics: clozapine and the benzamides in the prevention and treatment of tardive dyskinesia.
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003024:Clozapine / Q000627:therapeutic use*; D003984:Dibenzazepines / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000517:prevention & control; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D008787:Metoclopramide / Q000627:therapeutic use; D011446:Prospective Studies; D012559:Schizophrenia / Q000188:drug therapy; D013469:Sulpiride / Q000627:therapeutic use; D013976:Tiapamil Hydrochloride / Q000627:therapeutic use
D014150:Antipsychotic Agents; D001549:Benzamides; D003984:Dibenzazepines; D013469:Sulpiride; D003024:Clozapine; D006220:Haloperidol; D008787:Metoclopramide; D013976:Tiapamil Hydrochloride